Baudax Bio, Inc. (BXRX), a biotechnology company, announced Thursday that the U.S. Food and Drug Administration or FDA has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors.
from RTT - Before the Bell https://ift.tt/ZvuQodl
via IFTTT
No comments:
Post a Comment